logo-loader
viewSareum Holdings PLC

Sareum Holdings raises over a £1mln to advance preclinical work on its TYK2/JAK1 drugs

Sareum Holdings PLC's (LON:SAR) Tim Mitchell caught up with Proactive London's Andrew Scott following the news it's raised just over £1mln to advance the preclinincal work on its TYK2/JAK1 drugs SDC-1801 and SDC-1802.

Mitchell says they're exploring the potential benefit of the TYK2/JAK1 inhibitors against coronavirus (COVID-19) as well as in cancer and autoimmune diseases.

Preparatory work is being made to advance candidates towards human trials.

Quick facts: Sareum Holdings PLC

Price: 0.885 GBX

AIM:SAR
Market: AIM
Market Cap: £28.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

2 days, 21 hours ago

2 min read